Navigation Links
UNC study offers first clinical evidence of anti-cancer drug triggering viral infection
Date:4/12/2010

Chapel Hill, NC - Important advances in the fight against cancer have come as researchers proved that viruses and cancers interact in ways that were previously unknown to scientists.

A new study led by UNC scientists shows that a common cancer drug can activate a viral infection that, paradoxically, can help anti-viral medications eradicate virus-associated cancer.

The cooperative study, conducted by a team of UNC School of Medicine scientists and the UNC Project in Malawi, demonstrated for the first time in humans that a common drug used to treat Burkitt lymphoma can activate infection by the Epstein-Barr virus (EBV), a virus which typically lies latent inside the tumor cells of affected patients. The finding paves the way for a future study using both a cancer drug and an antiviral agent to eradicate both the active virus infection and the tumor. The findings are reported in the April 1 issue of the journal Clinical Cancer Research.

Margaret Gulley, MD, professor of pathology and laboratory medicine, said, "What we have learned from this work is a potential means of capitalizing on presence of viral genomes within tumor cells to alter those tumor cells in a way that makes them more susceptible to treatment. Our findings have implications for other EBV- related malignancies that, overall, are among the most common cancers worldwide." Gulley is a member of UNC Lineberger Comprehensive Cancer Center.

EBV infects more than 90 percent of the world's population and is associated with diseases ranging from infectious mononucleosis to lymphomas, gastric cancer and cancer of the nose and throat.

Burkitt lymphoma, which is associated with EBV, is rare in most parts of the world, but is endemic in sub-Saharan Africa. Burkitt lymphoma is an aggressive, fast-growing type of non-Hodgkin lymphoma that often occurs in children. The disease may affect the jaw, bowel, lymph nodes, or other organs

The study demonstrated that initiating treatment with the anti-cancer drug cyclophosphamide in children with Burkitt lymphoma simultaneously triggered an active EBV infection. The increased replication of EBV in cancer tissue makes these cells more susceptible to the antiviral drugs that kill cells containing replicating virus. Antiviral agents such as ganciclovir and valacyclovir are already in routine clinical use for treating active viral infections.

Researchers enrolled 21 patients with a confirmed diagnosis of EBV-related Burkitt lymphoma. The patients ranged in age from 5-15 and were under treatment with cyclophosphamide for their cancer. Through laboratory analysis of biopsy samples, researchers found that cyclophosphamide seems to induce the phase of viral infection most susceptible to antiviral therapy.

"The next step," explains Gulley," is to design a clinical trial using both cytoxan and an antiviral agent simultaneously." Plans for such a trial are already underway under the leadership of Carol Shores, MD, PhD, associate professor of surgery in UNC's Department of Otolaryngology/Head and Neck Surgery and senior author of the study.


'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-5905
University of North Carolina School of Medicine
Source:Eurekalert  

Related medicine news :

1. Casual Sex Doesnt Cause Emotional Damage: Study
2. Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks
3. Screening for Spinal Muscular Atrophy Not Cost-Effective: Study
4. New study finds possible source of beta cell destruction that leads to Type 1 diabetes
5. New Study Demonstrates Novel Use of Metabolic Imaging to Locate Sperm in Infertile Men -- Non-Invasive Imaging Procedure May Replace Invasive Techniques such as Testicula
6. Risk of stroke lower for recent Ontario immigrants: study
7. Definitive study confirms chemo benefit in postmenopausal breast cancer
8. Experimental stem cell treatment arrests acute lung injury in mice, study shows
9. Violence is part of the job say nurses as study shows only 1 in 6 incidents are reported
10. Controversial Autism Study Retracted by Medical Journal
11. Study Reveals Impact Of Health Insurance On Hispanics' Attitudes Towards Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UNC study offers first clinical evidence of anti-cancer drug triggering viral infection
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology: